Real-Life Use of Ramucirumab in Gastric Cancer in Spain: the RAMIS Study
Authors:
Open Access
- 16 February 2021
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (14) , 1777-1791
Abstract
Aims: To obtain real-world data on ramucirumab use and effectiveness for the treatment of advanced gastric cancer (AGC) or gastroesophageal junction adenocarcinoma (GEJ). Methods: Observational, re...Keywords
Funding Information
- Eli Lilly and Company
This publication has 22 references indexed in Scilit:
- Advanced gastric cancer: Current treatment landscape and future perspectivesWorld Journal of Gastroenterology, 2016
- Second-line treatment of metastatic gastric cancer: Current options and future directionsWorld Journal of Gastroenterology, 2015
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialThe Lancet Oncology, 2014
- Gastric Cancer: Descriptive Epidemiology, Risk Factors, Screening, and PreventionCancer Epidemiology, Biomarkers & Prevention, 2014
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialThe Lancet Oncology, 2014
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trialThe Lancet, 2014
- Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)European Journal of Cancer, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Epidemiology of gastric cancerWorld Journal of Gastroenterology, 2006
- Quality of life in patients with advanced gastric cancer treated with second-line chemotherapyCancer Chemotherapy and Pharmacology, 2005